Related Experiment Video
Updated: Aug 26, 2025
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Early surgical approaches in pediatric epilepsy - a systematic review and meta-analysis
Nicole Alexandra Frank1, Ladina Greuter2, Raphael Guzman2,3,4
1Department of Neurosurgery, University Hospital of Basel, Basel, Switzerland. franknicolealexandra@gmail.com.
Insights
Early epilepsy surgery in children under 3 years old is safe and effective for treating intractable epilepsy, with outcomes comparable to later surgery. Developmental improvements were observed in 26% of patients.
Area of Science:
- Pediatric Neurology
- Neurosurgery
- Epileptology
Background:
- Drug-resistant epilepsy affects up to 30% of children, with 10% eligible for surgery.
- Early surgical intervention in pediatric epilepsy is under investigation for optimal outcomes.
Approach:
- A systematic review and meta-analysis identified studies on pediatric epilepsy surgery (under 3 years) up to 2022.
- Analyzed seizure outcomes, complications, and developmental effects in 532 patients.
Key Points:
- Resective/disconnective surgery in 401 young children yielded favorable outcomes in 68%.
- No significant difference in seizure outcomes between early (<3 years) and later surgery.
- Vagus nerve stimulation (VNS) showed favorable outcomes in 52% overall.
- Developmental outcomes improved in 26% of patients; morbidity and mortality rates were low.
Conclusions:
- Epilepsy surgery, particularly before age 3, is a safe and feasible treatment for intractable pediatric epilepsy.
- Future prospective studies should focus on comparative seizure and developmental outcomes.
Introduction:
Drug-resistant epilepsy occurs in up to 30% of children suffering from seizures and about 10% qualify for surgical treatment. The aim of this systematic review and meta-analysis is to analyze the potential benefit of early epilepsy surgery in children concerning primarily seizure and developmental outcome.
Methods:
PubMed and Embase databases were searched using a systematic search strategy to identify studies on pediatric epilepsy surgery under 3 years from their inception up to 2022. Outcome measures were seizure outcome, postoperative complications, seizure onset, and reduction rate of antiepileptic drugs. A meta-analysis was thereafter performed for all included cohort studies. A p-value of < 0.05 was considered as statistically significant.
Results:
A total of 532 patients were analyzed with 401 patients (75%) receiving resective or disconnective surgery under the age of 3 years and 80 patients (15%) receiving surgery older than 3 years. The remaining 51 patients (9%) underwent VNS implantation. Pooled outcome analysis for resective/disconnective surgery showed favorable outcome in 68% (95% CI [0.63; 0.73]), while comparative analysis between the age groups showed no significant difference (77% early group and 75% late group; RR 1.03, 95% CI [0.73; 1.46] p = 0.75). Favorable outcome for the VNS cohort was seen in 52%, 65% in the early and 45.1% in the late group (RR 1.4393, 95% CI [0.87; 2.4] z = 1.42, p = 0.16). Developmental outcome was improved in 26%. Morbidity rate was moderate and showed no significant difference comparing the age groups, and overall surgical mortality rate was very low (0.1%).
Conclusion:
Epilepsy surgery in pediatric age, especially under the age of 3 years, is a feasible and safe way to treat intractable epilepsy. Further comparative studies of prospective nature, analyzing not only seizure but also developmental outcome, should be the focus of future studies.
